BioCryst Pharmaceuticals, Inc.
BCRX
$8.80
$0.222.56%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 75.92% | 94.10% | 45.38% | 45.85% | 41.67% |
| Total Other Revenue | -- | -13.49% | 126.70% | 127.92% | 128.43% |
| Total Revenue | 75.92% | 94.10% | 45.38% | 45.85% | 41.67% |
| Cost of Revenue | 15.15% | -1.37% | -4.71% | -7.70% | -16.41% |
| Gross Profit | 109.67% | 161.00% | 91.82% | 106.00% | 130.70% |
| SG&A Expenses | 23.23% | 29.32% | 33.39% | 33.97% | 28.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.13% | 16.71% | 16.53% | 14.72% | 6.54% |
| Operating Income | 835.76% | 27,254.26% | 316.23% | 200.13% | 140.58% |
| Income Before Tax | -787.37% | 407.51% | 94.67% | 78.02% | 75.46% |
| Income Tax Expenses | 66.43% | 83.19% | 801.95% | 723.58% | 57,100.00% |
| Earnings from Continuing Operations | -756.52% | 396.87% | 92.91% | 75.53% | 74.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -756.52% | 396.87% | 92.91% | 75.53% | 74.37% |
| EBIT | 835.76% | 27,254.26% | 316.23% | 200.13% | 140.58% |
| EBITDA | 771.18% | 20,141.83% | 353.05% | 211.00% | 145.65% |
| EPS Basic | -569.44% | 390.91% | 92.87% | 76.38% | 75.80% |
| Normalized Basic EPS | 624.42% | 428.74% | 101.04% | 81.71% | 72.87% |
| EPS Diluted | -578.94% | 378.68% | 91.85% | 75.42% | 75.59% |
| Normalized Diluted EPS | 602.39% | 416.09% | 100.08% | 81.35% | 72.85% |
| Average Basic Shares Outstanding | 5.22% | 1.54% | 1.85% | 3.63% | 5.51% |
| Average Diluted Shares Outstanding | 7.81% | 5.75% | 5.07% | 5.71% | 6.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |